Recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07874633· Phase 3· Pfizer· Source
Recruiting
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
NCT07827599· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
NCT07812597· Phase 2· Beijing QL Biopharmaceutical Co.,Ltd· Source
Contact: Shu Li, Doctor
Recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954· Phase 3· Pfizer· Source
Not yet recruiting
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source
Contact: zhengyu song
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759· Phase 2· Eli Lilly and Company· Source
Contact: Huixin Chen (principal investigator)
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099· Phase 2· Eli Lilly and Company· Source
Contact: Huixin Chen (principal investigator)
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· Phase 2· Eli Lilly and Company· Source
Contact: Huixin Chen (principal investigator)
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772· Phase 2· Eli Lilly and Company· Source
Contact: Huixin Chen (principal investigator)
Recruiting
Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled Study
NCT07539792· Phase 2· Nanfang Hospital, Southern Medical University· Source
Contact: Honghai Luo, Master of Medical Science
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Huixin Chen (principal investigator)
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Not yet recruiting
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)
NCT07274137· Phase 3· MindRank AI Ltd· Source
Contact: Zhan Lin
Active, not recruiting
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
NCT07230119· Phase 3· Beijing QL Biopharmaceutical Co.,Ltd· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things
NCT07126457· Nanfang Hospital, Southern Medical University· Source
Contact: Jian Guan, M.D
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Changqing Lin, Bachelor
Recruiting
Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis
NCT06307327· Nanfang Hospital, Southern Medical University· Source
Contact: Yunming Tian
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499· Phase 3· argenx· Source
Contact: Guowei Li, MD
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Ying He, Site 0326
Not yet recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Hailin Xiong, Doctor
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314· Nanfang Hospital, Southern Medical University· Source
Contact: Yunming Tian
Active, not recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897· Phase 3· Takeda· Source
Contact: Huixin Chen (principal investigator)
Active, not recruiting
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143· Phase 4· Guangdong Provincial People's Hospital· Source